已收盘 09-06 16:00:00 美东时间
+1.050
+10.57%
9月7日,Travere Therapeutics(TVTX.US)宣布,美国FDA完全批准“first-in-class”疗法Filspari(sparsentan)。
09-07 15:37
Citigroup analyst Carly Kenselaar maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $14 to $23.
09-07 02:47
Top Wall Street analysts changed their outlook on these top names. For a comple...
09-06 20:16
Travere Therapeutics (TVTX – Research Report), the Healthcare sector company, w...
08-31 00:55
Novartis (NYSE:NVS) has received FDA accelerated approval for its drug Fabhalta to be used in the reduction of proteinuria in adults with primary immunoglobulin A nephropathy, or IgAN, at risk of rapi...
08-08 04:57
4 analysts have expressed a variety of opinions on Travere Therapeutics (NASDAQ...
08-02 22:00
Travere Therapeutics (NASDAQ:TVTX) on Thursday said that it filed a prospectus for a mixed shelf offering, with the size undisclosed. The prospectus is not an offer to sell. SEC Filing. More on Traver...
08-02 05:47
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on T...
07-09 22:05
Travere Therapeutics (TVTX) has provided an announcement. During the Annual Mee...
05-14 04:25
Travere Therapeutics shares are trading higher following Q1 earnings.
05-07 23:20